Health-care companies rose as traders rotated back into sectors that are less sensitive to shifts in inflation and oil prices.
Sionna Therapeutics plunged more than 90% after the biotech company said it was shelving a highly anticipated cystic fibrosis drug candidate because it failed to meet the key endpoint in a proof-of-concept trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.